^
+ Follow CONNECT HOTLINE Tag
CONNECT HOTLINE
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 395220
                    [Title] => Anti-PAD drug found to have lipid modifying effects
                    [Summary] => 


Cilostazol, a drug popularly known for its antiplatelet effect preventing the formation of blood clots in the body’s blood vessels, has also been shown to have favorable effects on the body’s lipid or cholesterol profile, particularly the high density lipoprotein (HDL) and triglycerides.


HDL is also known as the good type of cholesterol, while triglycerides are a type of fat which when increased can also be associated with increased risk of heart attack and stroke.
[DatePublished] => 2007-04-19 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 361504 [Title] => 4 M Pinoys at risk of PAD [Summary] => According to the 2004 National Nutrition and Health Survey, there are almost four million Filipinos who are suffering from diabetes.

These people are constantly in danger of succumbing to the disease’s complications such as Peripheral Arterial Disease (PAD).

PAD, whose primary risk factor is diabetes, is a problem with blood flow in the arteries. The disease causes the arteries that normally supply blood to the muscle to get narrow or blocked so that less blood can flow through the artery.
[DatePublished] => 2006-10-05 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with